메뉴 건너뛰기




Volumn 33, Issue 2, 2015, Pages 423-431

Phase 1 study of the oral histone deacetylase inhibitor abexinostat in patients with Hodgkin lymphoma, non-Hodgkin lymphoma, or chronic lymphocytic leukaemia

Author keywords

Abexinostat; Efficacy; Lymphoma; Phase 1 study; Safety

Indexed keywords

ABEXINOSTAT; ANTINEOPLASTIC AGENT; BENZOFURAN DERIVATIVE; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID;

EID: 84940000336     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-015-0206-x     Document Type: Article
Times cited : (32)

References (25)
  • 1
    • 33748451151 scopus 로고    scopus 로고
    • Anticancer activities of histone deacetylase inhibitors
    • 1:CAS:528:DC%2BD28XptVCltrY%3D 16955068
    • Bolden JE, Peart MJ, Johnstone RW (2006) Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 5:769-784
    • (2006) Nat Rev Drug Discov , vol.5 , pp. 769-784
    • Bolden, J.E.1    Peart, M.J.2    Johnstone, R.W.3
  • 2
    • 84874410182 scopus 로고    scopus 로고
    • Histone deacetylase inhibitors (HDACIs): Multitargeted anticancer agents
    • 1:CAS:528:DC%2BC3sXktFCms70%3D 23459471
    • Ververis K, Hiong A, Karagiannis TC, Licciardi PV (2013) Histone deacetylase inhibitors (HDACIs): multitargeted anticancer agents. Biologics 7:47-60
    • (2013) Biologics , vol.7 , pp. 47-60
    • Ververis, K.1    Hiong, A.2    Karagiannis, T.C.3    Licciardi, P.V.4
  • 3
    • 84873636026 scopus 로고    scopus 로고
    • Histone deacetylase inhibitors: Novel agents in cancer treatment
    • 23372094
    • Glass E, Viale PH (2013) Histone deacetylase inhibitors: novel agents in cancer treatment. Clin J Oncol Nurs 17:34-40
    • (2013) Clin J Oncol Nurs , vol.17 , pp. 34-40
    • Glass, E.1    Viale, P.H.2
  • 4
    • 67349095775 scopus 로고    scopus 로고
    • Development of vorinostat: Current applications and future perspectives for cancer therapy
    • 1:CAS:528:DC%2BD1MXmsF2jt7k%3D 19181442
    • Richon VM, Garcia-Vargas J, Hardwick JS (2009) Development of vorinostat: current applications and future perspectives for cancer therapy. Cancer Lett 280:201-210
    • (2009) Cancer Lett , vol.280 , pp. 201-210
    • Richon, V.M.1    Garcia-Vargas, J.2    Hardwick, J.S.3
  • 5
    • 36148950997 scopus 로고    scopus 로고
    • FDA approval summary: Vorinostat for treatment of advanced primary cutaneous T-cell lymphoma
    • 1:CAS:528:DC%2BD2sXhtlOmurrL 17962618
    • Mann BS, Johnson JR, Cohen MH, Justice R, Pazdur R (2007) FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist 12:1247-1252
    • (2007) Oncologist , vol.12 , pp. 1247-1252
    • Mann, B.S.1    Johnson, J.R.2    Cohen, M.H.3    Justice, R.4    Pazdur, R.5
  • 6
    • 84857522968 scopus 로고    scopus 로고
    • Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy
    • 1:CAS:528:DC%2BC38XltlaqsrY%3D 22271479
    • Coiffier B, Pro B, Prince HM, Foss F, Sokol L, Greenwood M et al (2012) Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy. J Clin Oncol 30:631-636
    • (2012) J Clin Oncol , vol.30 , pp. 631-636
    • Coiffier, B.1    Pro, B.2    Prince, H.M.3    Foss, F.4    Sokol, L.5    Greenwood, M.6
  • 7
    • 77955604540 scopus 로고    scopus 로고
    • Investigational histone deacetylase inhibitors for non-Hodgkin lymphomas
    • 1:CAS:528:DC%2BC3cXhtVWqu7rL 20649502
    • Watanabe T (2010) Investigational histone deacetylase inhibitors for non-Hodgkin lymphomas. Expert Opin Investig Drugs 19:1113-1127
    • (2010) Expert Opin Investig Drugs , vol.19 , pp. 1113-1127
    • Watanabe, T.1
  • 8
    • 78651378094 scopus 로고    scopus 로고
    • Histone deacetylase inhibitors in Hodgkin lymphoma
    • 21127943
    • Buglio D, Younes A (2010) Histone deacetylase inhibitors in Hodgkin lymphoma. Invest New Drugs 28(Suppl 1):S21-S27
    • (2010) Invest New Drugs , vol.28 , pp. 21-S27
    • Buglio, D.1    Younes, A.2
  • 9
    • 83255170966 scopus 로고    scopus 로고
    • Treatment of relapsed or refractory chronic lymphocytic leukemia
    • Veliz M, Pinilla-Ibarz J (2012) Treatment of relapsed or refractory chronic lymphocytic leukemia. Cancer Control 19:37-53
    • (2012) Cancer Control , vol.19 , pp. 37-53
    • Veliz, M.1    Pinilla-Ibarz, J.2
  • 10
    • 66149161777 scopus 로고    scopus 로고
    • Combining PCI-24781, a novel histone deacetylase inhibitor, with chemotherapy for the treatment of soft tissue sarcoma
    • 1:CAS:528:DC%2BD1MXmtVKlsrw%3D 19417021
    • Lopez G, Liu J, Ren W, Wei W, Wang S, Lahat G et al (2009) Combining PCI-24781, a novel histone deacetylase inhibitor, with chemotherapy for the treatment of soft tissue sarcoma. Clin Cancer Res 15:3472-3483
    • (2009) Clin Cancer Res , vol.15 , pp. 3472-3483
    • Lopez, G.1    Liu, J.2    Ren, W.3    Wei, W.4    Wang, S.5    Lahat, G.6
  • 11
    • 33745087150 scopus 로고    scopus 로고
    • CRA-024781: A novel synthetic inhibitor of histone deacetylase enzymes with antitumor activity in vitro and in vivo
    • 1:CAS:528:DC%2BD28XltVWms7Y%3D 16731764
    • Buggy JJ, Cao ZA, Bass KE, Verner E, Balasubramanian S, Liu L et al (2006) CRA-024781: a novel synthetic inhibitor of histone deacetylase enzymes with antitumor activity in vitro and in vivo. Mol Cancer Ther 5:1309-1317
    • (2006) Mol Cancer Ther , vol.5 , pp. 1309-1317
    • Buggy, J.J.1    Cao, Z.A.2    Bass, K.E.3    Verner, E.4    Balasubramanian, S.5    Liu, L.6
  • 12
    • 77955960586 scopus 로고    scopus 로고
    • PCI-24781, a novel hydroxamic Acid HDAC inhibitor, exerts cytotoxicity and histone alterations via caspase-8 and FADD in leukemia cells
    • Rivera-Del VN, Gao S, Miller CP, Fulbright J, Gonzales C, Sirisawad M et al (2010) PCI-24781, a novel hydroxamic Acid HDAC inhibitor, exerts cytotoxicity and histone alterations via caspase-8 and FADD in leukemia cells. Int J Cell Biol 207420
    • (2010) Int J Cell Biol , pp. 207420
    • Rivera-Del, V.N.1    Gao, S.2    Miller, C.P.3    Fulbright, J.4    Gonzales, C.5    Sirisawad, M.6
  • 13
    • 77956335478 scopus 로고    scopus 로고
    • Histone deacetylase inhibitor (HDACI) PCI-24781 potentiates cytotoxic effects of doxorubicin in bone sarcoma cells
    • 1:CAS:528:DC%2BC3MXht1ems7Y%3D 20461381
    • Yang C, Choy E, Hornicek FJ, Wood KB, Schwab JH, Liu X et al (2011) Histone deacetylase inhibitor (HDACI) PCI-24781 potentiates cytotoxic effects of doxorubicin in bone sarcoma cells. Cancer Chemother Pharmacol 67:439-446
    • (2011) Cancer Chemother Pharmacol , vol.67 , pp. 439-446
    • Yang, C.1    Choy, E.2    Hornicek, F.J.3    Wood, K.B.4    Schwab, J.H.5    Liu, X.6
  • 14
    • 79956061602 scopus 로고    scopus 로고
    • Histone deacetylase inhibitor PCI-24781 enhances chemotherapy-induced apoptosis in multidrug-resistant sarcoma cell lines
    • 1:CAS:528:DC%2BC3MXms1Gktrc%3D 21508354
    • Yang C, Choy E, Hornicek FJ, Wood KB, Schwab JH, Liu X et al (2011) Histone deacetylase inhibitor PCI-24781 enhances chemotherapy-induced apoptosis in multidrug-resistant sarcoma cell lines. Anticancer Res 31:1115-1123
    • (2011) Anticancer Res , vol.31 , pp. 1115-1123
    • Yang, C.1    Choy, E.2    Hornicek, F.J.3    Wood, K.B.4    Schwab, J.H.5    Liu, X.6
  • 18
    • 45149100665 scopus 로고    scopus 로고
    • Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: A report from the international workshop on chronic lymphocytic leukemia updating the National Cancer Institute-Working Group 1996 guidelines
    • 2972576 1:CAS:528:DC%2BD1cXnsVOktrk%3D 18216293
    • Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Dohner H et al (2008) Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the international workshop on chronic lymphocytic leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 111:5446-5456
    • (2008) Blood , vol.111 , pp. 5446-5456
    • Hallek, M.1    Cheson, B.D.2    Catovsky, D.3    Caligaris-Cappio, F.4    Dighiero, G.5    Dohner, H.6
  • 19
    • 84881085302 scopus 로고    scopus 로고
    • Pharmacokinetic/pharmacodynamic modelling-based optimisation of administration schedule for the histone deacetylase inhibitor abexinostat (S78454/PCI-24781) in phase i
    • 1:CAS:528:DC%2BC3sXpvVyls7k%3D 23790467
    • Fouliard S, Robert R, Jacquet-Bescond A, du Rieu QC, Balasubramanian S, Loury D et al (2013) Pharmacokinetic/pharmacodynamic modelling-based optimisation of administration schedule for the histone deacetylase inhibitor abexinostat (S78454/PCI-24781) in phase I. Eur J Cancer 49:2791-2797
    • (2013) Eur J Cancer , vol.49 , pp. 2791-2797
    • Fouliard, S.1    Robert, R.2    Jacquet-Bescond, A.3    Du Rieu, Q.C.4    Balasubramanian, S.5    Loury, D.6
  • 21
    • 84939985066 scopus 로고    scopus 로고
    • BSA-adjusted dose? An old method to fight old bias
    • PAGE Accessed 30-9-2013
    • Fouliard S, Chenel M. BSA-adjusted dose? An old method to fight old bias. Poster presented at the Population Approach Group Europe meeting 2010. PAGE 2010; www.page-meeting.org. Accessed 30-9-2013
    • (2010) Population Approach Group Europe Meeting 2010
    • Fouliard, S.1    Chenel, M.2
  • 22
    • 84880707486 scopus 로고    scopus 로고
    • A phase II multicenter study of the histone deactelase inhibitor abexinostat (PCI-24781) in relapsed/refractory follicular lymphoma (FLp and mantle cell lymphoma (MCL)
    • Abstract 55
    • Evens AM, Vose JM, Harb W, Gordon LI, Langdon R, Grant B et al. A phase II multicenter study of the histone deactelase inhibitor abexinostat (PCI-24781) in relapsed/refractory follicular lymphoma (FLp and mantle cell lymphoma (MCL). Abstract 55. Blood 2013; 120 (Suppl)
    • (2013) Blood , pp. 120
    • Evens, A.M.1    Vose, J.M.2    Harb, W.3    Gordon, L.I.4    Langdon, R.5    Grant, B.6
  • 23
    • 84876460347 scopus 로고    scopus 로고
    • Hierarchy in somatic mutations arising during genomic evolution and progression of follicular lymphoma
    • 3587323 1:CAS:528:DC%2BC3sXjsFKms7Y%3D 23297126
    • Green MR, Gentles AJ, Nair RV, Irish JM, Kihira S, Liu CL et al (2013) Hierarchy in somatic mutations arising during genomic evolution and progression of follicular lymphoma. Blood 121:1604-1611
    • (2013) Blood , vol.121 , pp. 1604-1611
    • Green, M.R.1    Gentles, A.J.2    Nair, R.V.3    Irish, J.M.4    Kihira, S.5    Liu, C.L.6
  • 24
    • 84895815322 scopus 로고    scopus 로고
    • Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma
    • 3907271 1:CAS:528:DC%2BC3sXhvFyksbbL 24362818
    • Okosun J, Bodor C, Wang J, Araf S, Yang CY, Pan C et al (2014) Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma. Nat Genet 46:176-181
    • (2014) Nat Genet , vol.46 , pp. 176-181
    • Okosun, J.1    Bodor, C.2    Wang, J.3    Araf, S.4    Yang, C.Y.5    Pan, C.6
  • 25
    • 79958084461 scopus 로고    scopus 로고
    • A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer
    • 3111195 1:CAS:528:DC%2BC3MXntV2hsbg%3D 21559012
    • Munster PN, Thurn KT, Thomas S, Raha P, Lacevic M, Miller A et al (2011) A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer. Br J Cancer 104:1828-1835
    • (2011) Br J Cancer , vol.104 , pp. 1828-1835
    • Munster, P.N.1    Thurn, K.T.2    Thomas, S.3    Raha, P.4    Lacevic, M.5    Miller, A.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.